European research into chemical mixtures launched EU project EuroMix (European Test and Risk Assessment Strategies for Mixtures) was launched recently.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
More children subjected to CT scanning The number of medical examinations in which children are exposed to relatively high radiation doses has increased significantly over the last years.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Breast milk as indicator of environmental pollutants The 6th worldwide study into Persistent Organic Pollutants (POPs) in breast milk is about to commence.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.
Human and veterinary health sectors join forces for responsible use of antibiotics. Bacteria that are resistant to almost all antibiotics continue to spread across Europe. This was revealed by new figures from the European Centre for Disease Prevention and Control (ECDC).